Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
CRDF Cardiff Oncology
1.410
-0.080-5.37%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
8.14% 93K 33.82% 91K 2.78% 74K -1.91% 359K
Operating revenue
8.14% 93K 33.82% 91K 2.78% 74K -1.91% 359K
Cost of revenue
Gross profit
Operating expense
28.26% 9.09M 51.42% 10.53M 102.18% 11.15M 50.19% 29.21M
Selling and administrative expenses
5.02% 3.08M 8.74% 3.09M 76.29% 3.94M 44.08% 11.84M
-General and administrative expense
5.02% 3.08M 8.74% 3.09M 76.29% 3.94M 44.08% 11.84M
Research and development costs
44.66% 6.01M 80.82% 7.45M 119.82% 7.21M 54.65% 17.38M
Operating profit
-28.51% -8.99M -51.59% -10.44M -103.49% -11.07M -51.19% -28.86M
Net non-operating interest income expense
554.29% 458K 256.34% 253K 128.07% 130K 199.01% 264K
Non-operating interest income
-- 458K 256.34% 253K 128.07% 130K 193.96% 264K
Non-operating interest expense
-- -- -- -- -- -- -- 0
Other net income (expense)
-340.00% -36K -514.75% -253K -123.79% -49K 197.06% 300K
Gain on sale of security
-- -- -- -- -- -- 201.48% 285K
Other non- operating income (expenses)
-1,300.00% -36K -- -253K -4,800.00% -49K 153.11% 15K
Income before tax
-23.98% -8.57M -54.55% -10.44M -112.26% -10.99M -46.53% -28.29M
Income tax
Net income
-23.98% -8.57M -54.55% -10.44M -112.26% -10.99M -46.53% -28.29M
Net income continuous Operations
-23.98% -8.57M -54.55% -10.44M -112.26% -10.99M -46.53% -28.29M
Minority interest income
Net income attributable to the parent company
-23.98% -8.57M -54.55% -10.44M -112.26% -10.99M -46.53% -28.29M
Preferred stock dividends
0.00% 6K 0.00% 6K 0.00% 6K -99.27% 24K
Other preferred stock dividends
Net income attributable to common stockholders
-23.96% -8.58M -54.50% -10.45M -112.13% -11M -25.30% -28.32M
Basic earnings per share
-17.65% -0.2 -41.18% -0.24 -78.57% -0.25 32.41% -0.73
Diluted earnings per share
-17.65% -0.2 -41.18% -0.24 -78.57% -0.25 32.41% -0.73
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
CEO: Dr. Mark Erlander, PhD
Market: NASDAQ
Listing Date: 07/31/2003
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist